Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · IEX Real-Time Price · USD
13.16
0.39 (3.05%)
May 20, 2022 4:00 PM EDT - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 |
|---|---|---|---|
| Selling, General & Admin | 8.04 | 0.95 | 0.22 |
| Research & Development | 14.99 | 7.94 | 3.11 |
| Operating Expenses | 23.02 | 8.89 | 3.33 |
| Operating Income | -23.02 | -8.89 | -3.33 |
| Interest Expense / Income | -0.07 | 0.08 | 0 |
| Other Expense / Income | 0 | 0.65 | -0 |
| Pretax Income | -22.96 | -9.61 | -3.33 |
| Income Tax | 0 | 0 | 0 |
| Net Income | -22.96 | -9.61 | -3.33 |
| Net Income Common | -22.96 | -9.61 | -3.33 |
| Shares Outstanding (Basic) | 12 | 0 | 1 |
| Shares Outstanding (Diluted) | 12 | 0 | 1 |
| Shares Change | 4975.15% | -67.70% | - |
| EPS (Basic) | -1.87 | -40.31 | -4.44 |
| EPS (Diluted) | -1.87 | -40.31 | -4.44 |
| Free Cash Flow Per Share | -2.24 | -32.44 | -3.71 |
| Effective Tax Rate | -0.01% | 0.00% | -0.03% |
| EBITDA | -23.01 | -9.54 | -3.33 |
| EBIT | -23.03 | -9.54 | -3.33 |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).